EdgarLookup

Mama's Creations, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Mama's Creations, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
5.5%
Profit Margin
Net income ÷ revenue
6.2%
Return on Assets
Net income ÷ assets
0.63x
Debt-to-Equity
Total liabilities ÷ equity
+95.5%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2023 Jan 31, 2023 $95.42M Apr 26, 2023
FY2023 Jan 31, 2022 $48.80M Apr 26, 2023
FY2012 Jun 30, 2012 $0 Oct 1, 2012
FY2012 Jun 30, 2011 $0 Oct 1, 2012

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $171.71M Apr 14, 2026
FY2026 Jan 31, 2025 $123.33M Apr 14, 2026
FY2026 Jan 31, 2024 $103.28M Apr 14, 2026
FY2025 Jan 31, 2023 $93.19M Apr 8, 2025
FY2023 Jan 31, 2022 $47.08M Apr 26, 2023
FY2022 Jan 31, 2021 $40.76M May 27, 2022
FY2021 Jan 31, 2020 $33.75M Apr 21, 2021
FY2020 Jan 31, 2019 $28.47M Apr 23, 2020
FY2019 Jan 31, 2018 $27.54M Apr 23, 2019

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $43.05M Apr 14, 2026
FY2026 Jan 31, 2025 $30.53M Apr 14, 2026
FY2026 Jan 31, 2024 $30.33M Apr 14, 2026
FY2025 Jan 31, 2023 $19.42M Apr 8, 2025
FY2023 Jan 31, 2022 $11.85M Apr 26, 2023
FY2022 Jan 31, 2021 $12.74M May 27, 2022
FY2021 Jan 31, 2020 $9.98M Apr 21, 2021
FY2020 Jan 31, 2019 $9.89M Apr 23, 2020
FY2019 Jan 31, 2018 $9.26M Apr 23, 2019
FY2018 Jan 31, 2017 $7.22M May 16, 2018

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $5.29M Apr 14, 2026
FY2026 Jan 31, 2025 $3.71M Apr 14, 2026
FY2026 Jan 31, 2024 $6.56M Apr 14, 2026
FY2025 Jan 31, 2023 $2.30M Apr 8, 2025
FY2023 Jan 31, 2022 ($251.9K) Apr 26, 2023
FY2022 Jan 31, 2021 $4.07M May 27, 2022
FY2021 Jan 31, 2020 $1.53M Apr 21, 2021
FY2020 Jan 31, 2019 $453.5K Apr 23, 2020
FY2019 Jan 31, 2018 $319.7K Apr 23, 2019
FY2018 Jan 31, 2017 ($301.1K) May 16, 2018

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $7.11M Apr 14, 2026
FY2026 Jan 31, 2025 $4.88M Apr 14, 2026
FY2026 Jan 31, 2024 $8.89M Apr 14, 2026
FY2025 Jan 31, 2023 $2.82M Apr 8, 2025
FY2023 Jan 31, 2022 $82.8K Apr 26, 2023
FY2022 Jan 31, 2021 $3.48M May 27, 2022
FY2021 Jan 31, 2020 $2.08M Apr 21, 2021
FY2020 Jan 31, 2019 $1.47M Apr 23, 2020
FY2019 Jan 31, 2018 $1.06M Apr 23, 2019
FY2018 Jan 31, 2017 $456.0K May 16, 2018

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $288.0K Apr 14, 2026
FY2026 Jan 31, 2025 $455.0K Apr 14, 2026
FY2026 Jan 31, 2024 $414.0K Apr 14, 2026
FY2025 Jan 31, 2023 $135.0K Apr 8, 2025
FY2023 Jan 31, 2022 $120.7K Apr 26, 2023
FY2022 Jan 31, 2021 $110.7K May 27, 2022
FY2021 Jan 31, 2020 $114.6K Apr 21, 2021
FY2020 Jan 31, 2019 $130.9K Apr 23, 2020
FY2019 Jan 31, 2018 $138.0K Apr 23, 2019
FY2018 Jan 31, 2017 $153.3K May 16, 2018

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $35.65M Apr 14, 2026
FY2026 Jan 31, 2025 $25.20M Apr 14, 2026
FY2026 Jan 31, 2024 $21.03M Apr 14, 2026
FY2017 Jan 31, 2017 $42.0K Mar 23, 2017
FY2017 Jan 31, 2016 $24.0K Mar 23, 2017

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $11.42M Apr 14, 2026
FY2026 Jan 31, 2025 $5.18M Apr 14, 2026
FY2026 Jan 31, 2024 $11.62M Apr 14, 2026
FY2025 Jan 31, 2023 $5.51M Apr 8, 2025
FY2023 Jan 31, 2022 $909.8K Apr 26, 2023
FY2022 Jan 31, 2021 $3.70M May 27, 2022
FY2021 Jan 31, 2020 $1.81M Apr 21, 2021
FY2020 Jan 31, 2019 $1.44M Apr 23, 2020
FY2019 Jan 31, 2018 $1.32M Apr 23, 2019
FY2018 Jan 31, 2017 $357.2K May 16, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $1.65M Apr 14, 2026
FY2026 Jan 31, 2025 $5.10M Apr 14, 2026
FY2026 Jan 31, 2024 $786.0K Apr 14, 2026
FY2025 Jan 31, 2023 $593.0K Apr 8, 2025
FY2023 Jan 31, 2022 $10.41M Apr 26, 2023
FY2022 Jan 31, 2021 $419.4K May 27, 2022
FY2021 Jan 31, 2020 $268.1K Apr 21, 2021
FY2020 Jan 31, 2019 $1.03M Apr 23, 2020
FY2019 Jan 31, 2018 $1.47M Apr 23, 2019
FY2018 Jan 31, 2017 $552.9K May 16, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $85.70M Apr 14, 2026
FY2026 Jan 31, 2025 $47.06M Apr 14, 2026
FY2025 Jan 31, 2024 $45.10M Apr 8, 2025
FY2024 Jan 31, 2023 $34.59M Apr 24, 2024
FY2023 Jan 31, 2022 $30.03M Apr 26, 2023
FY2022 Jan 31, 2021 $14.05M May 27, 2022
FY2021 Jan 31, 2020 $9.94M Apr 21, 2021
FY2020 Jan 31, 2019 $7.67M Apr 23, 2020
FY2019 Jan 31, 2018 $7.27M Apr 23, 2019
FY2018 Jan 31, 2017 $5.06M May 16, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $33.08M Apr 14, 2026
FY2026 Jan 31, 2025 $22.17M Apr 14, 2026
FY2025 Jan 31, 2024 $25.52M Apr 8, 2025
FY2024 Jan 31, 2023 $22.07M Apr 24, 2024
FY2023 Jan 31, 2022 $21.92M Apr 26, 2023
FY2022 Jan 31, 2021 $5.74M May 27, 2022
FY2021 Jan 31, 2020 $9.54M Apr 21, 2021
FY2020 Jan 31, 2019 $8.95M Apr 23, 2020
FY2019 Jan 31, 2018 $9.21M Apr 23, 2019
FY2018 Jan 31, 2017 $7.74M May 16, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $52.62M Apr 14, 2026
FY2026 Jan 31, 2025 $24.90M Apr 14, 2026
FY2026 Jan 31, 2024 $19.58M Apr 14, 2026
FY2026 Jan 31, 2023 $12.52M Apr 14, 2026
FY2025 Jan 31, 2022 $8.11M Apr 8, 2025
FY2023 Jan 31, 2021 $8.31M Apr 26, 2023
FY2022 Jan 31, 2020 $402.1K May 27, 2022
FY2021 Jan 31, 2019 ($1.28M) Apr 21, 2021
FY2020 Jan 31, 2018 ($1.93M) Apr 23, 2020
FY2019 Jan 31, 2017 ($2.68M) Apr 23, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $9.45M Apr 14, 2026
FY2026 Jan 31, 2025 $8.63M Apr 14, 2026
FY2025 Jan 31, 2024 $8.63M Apr 8, 2025
FY2024 Jan 31, 2023 $8.63M Apr 24, 2024
FY2023 Jan 31, 2022 $8.63M Apr 26, 2023

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $5.45M Apr 14, 2026
FY2026 Jan 31, 2025 $164.0K Apr 14, 2026
FY2025 Jan 31, 2024 ($3.55M) Apr 8, 2025
FY2024 Jan 31, 2023 ($10.06M) Apr 24, 2024
FY2023 Jan 31, 2022 ($12.33M) Apr 26, 2023
FY2022 Jan 31, 2021 ($12.08M) May 27, 2022
FY2021 Jan 31, 2020 ($16.14M) Apr 21, 2021
FY2020 Jan 31, 2019 ($17.68M) Apr 23, 2020
FY2019 Jan 31, 2018 ($18.13M) Apr 23, 2019
FY2018 Jan 31, 2017 ($18.36M) May 16, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $19.95M Apr 14, 2026
FY2026 Jan 31, 2025 $7.15M Apr 14, 2026
FY2025 Jan 31, 2024 $11.02M Apr 8, 2025
FY2024 Jan 31, 2023 $4.38M Apr 24, 2024
FY2023 Jan 31, 2022 $850.6K Apr 26, 2023
FY2022 Jan 31, 2021 $3.19M May 27, 2022
FY2021 Jan 31, 2020 $393.7K Apr 21, 2021
FY2020 Jan 31, 2019 $609.4K Apr 23, 2020
FY2019 Jan 31, 2018 $581.3K Apr 23, 2019
FY2019 Jan 31, 2017 $670.8K Apr 23, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 $5.59M Apr 14, 2026
FY2020 Jan 31, 2020 $4.08M Apr 23, 2020
FY2019 Jan 31, 2019 $5.97M Apr 23, 2019
FY2018 Jan 31, 2018 $5.75M May 16, 2018
FY2017 Jan 31, 2017 $4.88M Mar 23, 2017
FY2016 Jan 31, 2016 $4.40M Apr 21, 2016

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 0 Apr 14, 2026
FY2026 Jan 31, 2025 0 Apr 14, 2026
FY2026 Jan 31, 2024 0 Apr 14, 2026
FY2025 Jan 31, 2023 0 Apr 8, 2025
FY2023 Jan 31, 2022 0 Apr 26, 2023
FY2022 Jan 31, 2021 0 May 27, 2022
FY2021 Jan 31, 2020 0 Apr 21, 2021
FY2020 Jan 31, 2019 0 Apr 23, 2020
FY2019 Jan 31, 2018 0 Apr 23, 2019
FY2018 Jan 31, 2017 0 May 16, 2018

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 0 Apr 14, 2026
FY2026 Jan 31, 2025 0 Apr 14, 2026
FY2026 Jan 31, 2024 0 Apr 14, 2026
FY2025 Jan 31, 2023 0 Apr 8, 2025
FY2023 Jan 31, 2022 0 Apr 26, 2023
FY2022 Jan 31, 2021 0 May 27, 2022
FY2021 Jan 31, 2020 0 Apr 21, 2021
FY2020 Jan 31, 2019 0 Apr 23, 2020
FY2019 Jan 31, 2018 0 Apr 23, 2019
FY2018 Jan 31, 2017 0 May 16, 2018

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2026 Jan 31, 2026 40.66M Apr 14, 2026
FY2026 Jan 31, 2025 37.60M Apr 14, 2026
FY2025 Jan 31, 2024 37.26M Apr 8, 2025
FY2024 Jan 31, 2023 36.09M Apr 24, 2024
FY2023 Jan 31, 2022 35.76M Apr 26, 2023
FY2022 Jan 31, 2021 35.60M May 27, 2022
FY2021 Jan 31, 2020 31.99M Apr 21, 2021
FY2020 Jan 31, 2019 31.87M Apr 23, 2020
FY2019 Jan 31, 2018 31.75M Apr 23, 2019
FY2018 Jan 31, 2017 27.81M May 16, 2018